FARON PHARMACEUTICALS OY ORD NPV (DI) news, videos and press releases
For more news please use our advanced search feature.
FARON PHARMACEUTICALS OY ORD NPV (DI) - More news...
FARON PHARMACEUTICALS OY ORD NPV (DI) - More news...
- Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024
- Faron Confirms Plans for the Coming Months Under New Leadership
- Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML
- Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab
- Faron’s Financial Statement Release January 1 to December 31, 2023
- Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population
- Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial
- Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting
- Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine
- Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS
- Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting
- Inside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade Register
- Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients
- Faron to Host Webcast to Discuss New Data From Phase I/II BEXMAB Study of Bexmarilimab and Provide Update on the Development Outlook for Next 6-9 Months
- Faron Pharmaceuticals Announces Board Changes
- Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting
- Faron Appoints Dr. Birge Berns, MD as Interim Chief Medical Officer
- Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Faron Reports Half-Year Financial Results, January 1 – June 30, 2023
- Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia
- Faron Pharmaceuticals Notice of Half-Year Financial Results
- Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS
- Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update
- Faron Pharmaceuticals Oy: Interim Results for the six months ended 30 June 2017
- Faron Pharmaceuticals Oy: Faron announces that US FDA proposes proceeding directly to BLA submission for Traumakine® following completion of European and Japanese Phase III studies
- Faron Pharmaceuticals Oy: Final Results for the year ended 31 December 2016
